Spark Therapeutics is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

Type
Public
HQ
Philadelphia, US
Founded
2013
Size (employees)
213 (est)
Spark Therapeutics was founded in 2013 and is headquartered in Philadelphia, US
Report incorrect company information

Key People/Management at Spark Therapeutics

Jeffrey D. Marrazzo

Jeffrey D. Marrazzo

Co-Founder, President and CEO
J. Fraser Wright

J. Fraser Wright

Scientific Co-Founder and CTO
Katherine A. High

Katherine A. High

Scientific Co-Founder

Spark Therapeutics Office Locations

Spark Therapeutics has an office in Philadelphia
Philadelphia, US (HQ)
3737 Market St
Show all (1)
Report incorrect company information

Spark Therapeutics Financials and Metrics

Spark Therapeutics Financials

Spark Therapeutics's revenue was reported to be $12.07 m in FY, 2017
USD

Revenue (FY, 2017)

12.1 m

Net income (FY, 2017)

(253.5 m)

EBIT (FY, 2017)

(258.5 m)

Market capitalization (20-Apr-2018)

2.7 b

Cash (31-Dec-2017)

96.7 m

EV

2.6 b
Spark Therapeutics's current market capitalization is $2.7 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

633.9 k22.1 m20.2 m12.1 m

Revenue growth, %

3380%(9%)

General and administrative expense

7.9 m23.4 m48.1 m111.1 m

R&D expense

16.4 m46 m86.4 m135.2 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

2.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.5 m

General and administrative expense

3.7 m6.3 m6.5 m8.9 m10.7 m12 m21.4 m26.7 m

R&D expense

8.3 m9.3 m11.8 m18.3 m19.6 m22.4 m32.7 m33 m

Operating expense total

12 m15.7 m18.3 m27.1 m30.3 m34.4 m54.1 m78.5 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

74.6 m293.5 m58.9 m96.7 m

Accounts Receivable

244.4 k16.9 m16.8 m

Current Assets

77.4 m311.6 m314.6 m533.2 m

PP&E

12.7 m17 m19.8 m61.7 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

234.4 m223 m212.2 m275 m225 m90.6 m27.5 m36.8 m

Accounts Receivable

669.4 k933.1 k1.3 m812.8 k1.2 m1 m5.9 m5 m

Current Assets

235.9 m225.1 m214.3 m277.8 m335.3 m309.2 m263.4 m226.3 m

PP&E

13.4 m13.5 m14.2 m18.4 m19.6 m19.8 m23.1 m25.5 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(24.3 m)(47.1 m)(123.7 m)(253.5 m)

Depreciation and Amortization

169.8 k1.7 m3.6 m4.9 m

Accounts Payable

2.3 m9.1 m10 m13 m

Cash From Operating Activities

10.4 m(47.5 m)(80.4 m)(154.5 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(9.7 m)(24.1 m)(41 m)(25.6 m)(54.3 m)(86.8 m)(52.3 m)(126.6 m)

Depreciation and Amortization

370.6 k797.2 k1.2 m744.1 k1.7 m2.6 m1 m2.2 m

Accounts Payable

870.4 k3.2 m7.7 m(1.1 m)(2 m)4.2 m(2.7 m)4.8 m

Cash From Operating Activities

(8.9 m)(19.3 m)(29.7 m)(7.7 m)(31.1 m)(51.8 m)(33.1 m)(75.9 m)
USDY, 2017

EV/EBIT

-10.1 x

EV/CFO

-16.9 x

Revenue/Employee

67.2 k

Financial Leverage

1.2 x
Show all financial metrics

Spark Therapeutics Operating Metrics

FY, 2016

Patents and Patent Applications

297
Show all operating metrics
Report incorrect company information